NYSEAM:LCTXBiotechs
Lineage Cell Therapeutics (LCTX) Returns To Loss In Q1 2026 Challenging Profitability Narratives
Lineage Cell Therapeutics (LCTX) opened 2026 with Q1 revenue of US$1.7 million and a basic EPS loss of US$0.02, as net income excluding extraordinary items came in at a loss of US$4.8 million. The company has seen quarterly revenue move between US$1.5 million and US$6.6 million over the past year, while EPS has ranged from a loss of around US$0.13 per share to a small profit of US$0.00 per share, presenting a mixed picture regarding the path toward better margins. For investors, the latest...